Trial reportNeurology2011
Intrathecal effects of daclizumab treatment of multiple sclerosis.
Trial report in Neurology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Daclizumab for relapsing remitting multiple sclerosis.The Cochrane database of systematic reviews · 2013Pooled it
- Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.Clinical and experimental immunology · 2015Trial
- CNS vasculitis in a patient with MS on daclizumab monotherapy.Neurology · 2013Trial
- The ratio of circulating CD56Heliyon · 2024Article
- Natural killer cells in the central nervous system.Cell communication and signaling : CCS · 2023Review
- CD3Journal of neuroimmunology · 2023Article
- Article
- Natural Killer Cells in Multiple Sclerosis: Entering the Stage.Frontiers in immunology · 2022Review
- Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis.Frontiers in immunology · 2022Review
- Prognostic value of natural killer cell/T cell ratios for disease activity in multiple sclerosis.European journal of neurology · 2021Article
- Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.BMJ neurology open · 2021Article
- The Role of Natural Killer Cells in Autoimmune Diseases.Frontiers in immunology · 2021Review
- CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis.Journal of clinical medicine · 2020Review
- Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.Frontiers in immunology · 2020Article
- Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping.Frontiers in neurology · 2020Article
- Daclizumab Therapy for Multiple Sclerosis.Cold Spring Harbor perspectives in medicine · 2019Review
- Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.Journal of neuroinflammation · 2019Article
- Article
- The effects of interleukin-2 on immune response regulation.Mathematical medicine and biology : a journal of the IMA · 2018Article
- Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectivesWe previously reported that daclizumab, a humanized monoclonal antibody against CD25, reduced contrast-enhancing lesions (CEL) in patients with multiple sclerosis (MS) who were suboptimal responders to interferon-β and that this response correlated with expansion of CD56(bright) NK cells. These data have been reproduced in a placebo-controlled multicenter trial (CHOICE study). The current study investigates whether daclizumab monotherapy reduces CEL in untreated patients with relapsing-remitting MS (RRMS) and the effects of daclizumab on the intrathecal immune system.
methodsSixteen patients with RRMS with high inflammatory activity were enrolled in an open-label, baseline-vs-treatment, phase II trial of daclizumab monotherapy for 54 weeks and followed by serial clinical and MRI examinations and immunologic biomarkers measured in the whole blood and CSF.
resultsThe trial achieved predefined outcomes. There was an 87.7% reduction in brain CEL (primary) and improvements in Multiple Sclerosis Functional Composite (secondary), Scripps Neurologic Rating Scale, and Expanded Disability Status Scale (tertiary) outcomes. There was significant expansion of CD56(bright) NK cells in peripheral blood and CSF, with resultant decrease in T cells/NK cells and B cells/NK cells ratios and IL-12p40 in the CSF. Surprisingly, CD25 Tac epitope was equally blocked on the immune cells in the CSF and in peripheral blood.
conclusionsDaclizumab monotherapy inhibits formation of MS plaques in patients with RRMS and immunoregulatory NK cells may suppress activation of pathogenic immune responses directly in the CNS compartment. CLASSIFICATION OF EVIDENCE: The study provides Class III evidence that daclizumab reduces the number of contrast-enhancing lesions in treatment-naive patients with RRMS over a 54-week period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.